Insider Selling: Aveanna Healthcare (NASDAQ:AVAH) CFO Sells $141,424.02 in Stock

Aveanna Healthcare Holdings Inc. (NASDAQ:AVAH) CFO Matthew Buckhalter sold 17,289 shares of the firm’s stock in a transaction on Wednesday, December 31st. The shares were sold at an average price of $8.18, for a total value of $141,424.02. Following the transaction, the chief financial officer owned 455,320 shares in the company, valued at approximately $3,724,517.60. This trade represents a 3.66% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Matthew Buckhalter also recently made the following trade(s):

• On Friday, January 2nd, Matthew Buckhalter sold 18,340 shares of Aveanna Healthcare stock. The stock was sold at an average price of $7.85, for a total transaction of $143,969.00.
• On Tuesday, December 30th, Matthew Buckhalter sold 17,448 shares of Aveanna Healthcare stock. The shares were sold at an average price of $8.36, for a total transaction of $145,865.28.

Aveanna Healthcare Stock Down 1.1%

Aveanna Healthcare stock opened at $8.08 on Monday. Aveanna Healthcare Holdings Inc. has a fifty-two week low of $3.67 and a fifty-two week high of $10.32. The company has a debt-to-equity ratio of 140.39, a quick ratio of 1.23 and a current ratio of 1.23. The firm’s 50-day simple moving average is $8.92 and its 200 day simple moving average is $7.52. The stock has a market cap of $1.69 billion, a PE ratio of 22.44 and a beta of 2.06.

Aveanna Healthcare (NASDAQ:AVAH) last posted its earnings results on Monday, May 22nd. The company reported $0.04 EPS for the quarter. Aveanna Healthcare had a net margin of 3.29% and a negative return on equity of 143.55%. The firm had revenue of $450.53 million for the quarter. Research analysts predict that Aveanna Healthcare Holdings Inc. will post -0.06 EPS for the current fiscal year.

Trending Headlines about Aveanna Healthcare

Here are the key news stories impacting Aveanna Healthcare this week:

• Negative Sentiment: CEO Jeff Shaner sold multiple blocks (roughly 83,000+ shares across Dec. 30–Jan. 2 in the filings), at prices around $8.18–$8.36, reducing his stake by about 1–1.2% in individual trades while retaining a multi‑million‑share holding — investors may view repeated CEO sales as a negative signal. SEC filing — Jeff Shaner
• Negative Sentiment: CFO Matthew Buckhalter executed several sales (totaling ~70,000+ shares across Dec. 30–Jan. 2) at roughly $7.85–$8.36, each reducing his position by ~3.5–4%. Repeated CFO sales can raise governance/comfort concerns for short‑term holders. SEC filing — Matthew Buckhalter
• Negative Sentiment: CAO Deborah Stewart sold multiple blocks (~34,000+ shares across Dec. 30–Jan. 2) at similar price levels, trimming her stake by ~4% in reported trades while keeping a substantial holding — another senior exec sale that may pressure sentiment. SEC filing — Deborah Stewart
• Negative Sentiment: Insider Edwin C. Reisz sold multiple tranches (~51,000+ shares across Dec. 30–Jan. 2) at $7.85–$8.36, reducing his position by ~1.2% in several filings. Multiple insider sellers across ranks amplify negative interpretation. SEC filing — Edwin C. Reisz
• Negative Sentiment: Insider Patrick A. Cunningham reported several sales (~36,000+ shares across Dec. 30–Jan. 2) at similar price points, lowering his stake by ~3.6–4.1% in the disclosed trades. Collective insider selling increases perceived supply risk. SEC filing — Patrick A. Cunningham

Hedge Funds Weigh In On Aveanna Healthcare

A number of institutional investors and hedge funds have recently added to or reduced their stakes in AVAH. Dynamic Technology Lab Private Ltd increased its stake in shares of Aveanna Healthcare by 8.9% in the third quarter. Dynamic Technology Lab Private Ltd now owns 14,149 shares of the company’s stock worth $126,000 after purchasing an additional 1,151 shares in the last quarter. Barclays PLC lifted its stake in shares of Aveanna Healthcare by 0.8% during the 3rd quarter. Barclays PLC now owns 179,359 shares of the company’s stock valued at $1,591,000 after buying an additional 1,366 shares in the last quarter. Franklin Resources Inc. boosted its holdings in Aveanna Healthcare by 4.5% in the 3rd quarter. Franklin Resources Inc. now owns 35,630 shares of the company’s stock worth $316,000 after buying an additional 1,528 shares during the period. Olympiad Research LP boosted its holdings in Aveanna Healthcare by 7.5% in the 3rd quarter. Olympiad Research LP now owns 31,621 shares of the company’s stock worth $280,000 after buying an additional 2,200 shares during the period. Finally, Rhumbline Advisers grew its stake in Aveanna Healthcare by 4.0% in the 1st quarter. Rhumbline Advisers now owns 75,581 shares of the company’s stock valued at $410,000 after buying an additional 2,918 shares in the last quarter. Institutional investors own 87.96% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on AVAH. UBS Group raised their target price on Aveanna Healthcare from $9.00 to $9.50 and gave the company a “neutral” rating in a research report on Friday, November 7th. JPMorgan Chase & Co. upgraded shares of Aveanna Healthcare from an “underweight” rating to a “neutral” rating and increased their price target for the company from $6.00 to $10.00 in a research report on Thursday, September 18th. BMO Capital Markets started coverage on shares of Aveanna Healthcare in a research report on Thursday, November 13th. They issued an “outperform” rating and a $11.00 price objective on the stock. Royal Bank Of Canada boosted their target price on shares of Aveanna Healthcare from $8.00 to $10.00 and gave the company a “sector perform” rating in a research note on Friday, October 24th. Finally, William Blair initiated coverage on shares of Aveanna Healthcare in a research note on Monday, December 8th. They set an “outperform” rating for the company. Five analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $10.69.

About Aveanna Healthcare

Aveanna Healthcare, Inc (NASDAQ: AVAH) is a national provider of in-home health care services, specializing in pediatric skilled nursing, therapy, and related support for medically complex and chronically ill children. The company delivers a range of clinical and therapeutic solutions designed to enable patients to receive care in the comfort of their own homes, reducing the need for hospital stays and long-term institutional care. Aveanna’s offerings include registered nursing, physical, occupational and speech therapy, behavioral health counseling, and durable medical equipment coordination.

In addition to pediatric home health services, Aveanna operates adult home health and personal care support programs, assisting elderly and disabled adults with daily living activities, medication management, and rehabilitation therapies.